Search Within

Gary Schwartz

  1. "David D'Adamo"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (8)
Groups
  1. Department of Medicine (13)
  2. Solid Tumor Oncology Division (12)
  3. Sarcoma Service (9)
  4. GSK Faculty (6)
  5. Tow Center for Developmental Oncology (TCDO) (6)
  6. Department of Pathology and Laboratory Medicine (5)

More Groups

People
  1. David D'Adamo (16)
  2. Robert Maki (13)
  3. Mary Keohan (9)
  4. Cristina Antonescu (4)
  5. Kelly Scheu (4)
  6. David Ilson (3)

More People

Years
  1. 2013 (2)
  2. 2012 (1)
  3. 2011 (1)
  4. 2010 (1)
  5. 2009 (2)
  6. 2008 (1)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Clinical Cancer Research (2)
  3. Annals of Oncology (1)
  4. Sarcoma (1)
Publishers
  1. American Society of Clinical Oncology (12)
  2. American Association for Cancer Research (2)
  3. Hindawi Publishing Corporation (1)
  4. Oxford University Press (1)

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447)
    Meeting Abstract

    Shah, M. A.; Ramanathan, R. K.; Ilson, D.; Randazzo, J.; Schwartz, G. K.; Tse, A.; D'adamo, D.; Levner, A.; Capanu, M.; Kelsen, D. P.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma
    Meeting Abstract

    D'adamo, D. R.; Scheu, K.; Singer, S.; Schwartz, G. K.; Maki, R. G.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna
    Journal Article

    Shah, M. A.; Ramanathan, R. K.; Ilson, D. H.; Levnor, A.; D'adamo, D.; O'reilly, E.; Tse, A.; Trocola, R.; Schwartz, L.; Capanu, M.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Shah, M. A.; Ilson, D.; Ramanathan, R. K.; Levner, A.; D'adamo, D.; Schwartz, L.; Casper, E.; Schwartz, G. K.; Kelsen, D. P.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas
    Journal Article

    D'adamo, D. R.; Anderson, S. E.; Albritton, K.; Yamada, J.; Riedel, E.; Scheu, K.; Schwartz, G. K.; Chen, H.; Maki, R. G.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Cardiac toxicity in a phase II study of doxorubicin (DOX) and bevacizumab (BEV) for patients (pts) with metastatic soft-tissue sarcomas
    Meeting Abstract

    D'adamo, D. R.; Anderson, S.; Albritton, K.; Yamada, J.; Riedel, E.; Scheu, K.; Schwartz, G. K.; Chen, H.; Maki, R. G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save